Administering MSCs after stroke improves functional neurologic outcomes, reduces infarct sizes, increases survival of neurons, and normalizes biochemical parameters through modulating ER stress-mediated apoptosis through the BDNF/TrkB signaling pathway. This evidence concerns the gene NTRK2 and stroke disorder.